BioSpace News Archive

The COVID-19 saliva screening test potential market will observe revolutionary growth across the assessment period of 2020-2030.

Autoinjector advances are empowering patients, specifically first-time patients, to infuse themselves with prescriptions with lower mistake rates and less tension.

Calliditas Therapeutics AB, and STADA Arzneimittel AG announced that they have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy in the European Economic Area member states, Switzerland and the UK.

bluebird bio, Inc. announced that the European Commission has granted marketing authorization of SKYSONA™, a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen -matched sibling hematopoietic stem cell donor is not available.

LumiThera Inc., a commercial stage medical device company offering a photobiomodulation treatment for ocular damage and disease, announced the final topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients.

Copenhagen, Denmark; July 21, 2021 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,433 million in the second quarter of 2021.

Congenica Receives CE Mark for Genomic Analysis Software Cambridge, United Kingdom.

Medifast, Inc . (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2021 on Wednesday, August 4, 2021 , after market close.

Bruker Corporation announced it will report second quarter 2021 financial results on Monday, August 2, 2021, after the market closes.

Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, announced the closing of a $68 million Series D financing and provided a pipeline update.